anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A pharmaceutical composition for preventing brain cancer containing Patriniae radix ethanol extract is provided to prevent and treat human brain cancer including primary brain tumor or metastatic brain tumor. CONSTITUTION: A composition for preventing and treating brain cancer contains Patriniae radix ethanol extract as an active ingredient. The ethanol is 95% ethanol. The composition further contains pharmaceutically acceptable carrier. The brain cancer includes primary brain tumor or metastatic brain tumor. The pharmaceutical composition is used by topical or subcutaneous administration.
PURPOSE:To obtain a modified SOD by bonding an SOD useful for the remedy of tissue disorder caused by O2<-> generated from oxygen molecule in a living body with a compound having pharmacological activity and useful as a drug. CONSTITUTION:A modified SOD (superoxide dismutase) is produced by bonding a carboxyl group (or amino group) of a compound having physiological activity to an amino group (or carboxyl group) of SOD using a carbodiimide and separating and purifying the objective substance e.g. by gel-filtration. The physiologically active compound is those having a molecular weight of 150-400, exhibiting anti-inflammatory action and having functional group such as amino group, carboxyl group, etc., e.g. indomethacin or ketoprofen. The SOD used as a starting material is human SOD produced e.g. by genetic engineering technique. The amount of the physiologically active compound to be bonded to SOD is preferably 1-10mol. per 1mol. of SOD.
Aloe polysaccharides (APs) display cognition-improving properties, but the underlying mechanisms remain unclear. Herein, AP supplementation for 24 weeks significantly improved cognitive behavioral disturbances caused by a high-fat diet. Moreover, APs notably reshaped the structure of the gut microbiota, which was manifested by increasing the relative abundance of Alloprevotella, Alistipes, Romboutsia, Turicibacter, Prevotellaceae_UCG-001, and Akkermansia while reducing the abundance of Parasutterella, Staphylococcus, Helicobacter, Enterococcus, and Erysipelatoclostridium. Notably, the gut barrier damage and LPS leakage caused by HF were recovered by APs. Additionally, with the improvement of intestinal barrier integrity, oxidative stress and inflammation in the brain and jejunum were significantly ameliorated. Furthermore, the expression of genes associated with cognitive impairment and the intestinal tract barrier was up-regulated (CREB, BDNF, TrkB, ZO-1 and occludin), while the expression of genes associated with inflammatory factors was down-regulated (IL-1β, IL-6, and TNF-α). Finally, we observed a significant correlation among cognition-related genes, gut microbiota, oxidative stress, and inflammation in the HF-AP group. Together, our findings suggest that altered gut microbiota composition and improved gut barrier integrity may be important targets for potentially improving high-fat diet-induced cognitive impairment.
Post-polio syndrome (PPS) brings new challenges for polio survivors, including muscle decline, pain, depression, and diminished quality of life. This study explored the potential of REAC neuromodulatory treatments to ease pain, improve mood, and enhance quality of life in PPS patients. 17 individuals with PPS (average age 54.8) received three REAC treatments: Neuro Postural Optimization, Neuro Psycho Physical Optimization, and Neuro Psycho Physical Optimization-Cervico Brachial. Pain, depression, anxiety, stress, and quality of life were assessed before and after using established scales. REAC treatments significantly reduced pain across various dimensions, along with depression, anxiety, and stress levels. Additionally, patients reported improved physical and psychological quality of life. This study suggests REAC neuromodulatory treatments as a promising non-invasive option to improve pain, emotional well-being, and quality of life in individuals with PPS.
The study design is a single center, open label, double arm study with no control and no randomization. We will enroll 50 patients who are adjusted contact lens wearers who have corrected visual acuity of 20/25 or better at distance. 25 patients will be in daily disposable contact lens of varied manufacturers. The other 25 will be in monthly disposable contact lenses of varied manufacturers. Subjects will insert the Miebo eye drops four times a day, and with their contact lenses removed every day. Subjects will be required to wait at least 30 minutes before inserting their lenses after drop use. Subjects will be seen on day 0 for initial screening, on day 7 and finally on day 30. The window for visits on day 7 is +/-3 and for day 30 +/- 7 days. Visits on day 7 and 30 will be conducted at least one hour post Miebo insertion. Overall vision and comfort will be assessed during the study. The primary endpoint is to show that Miebo eye drops are safe to use in contact lens wearers. The secondary endpoint is to show changes in comfort in contact lens wearing individuals.
Advances in medical imaging can provide useful information to guide and look at the response to treatment. Previous studies suggest early changes in the tumor after radiation treatment may be detectable using special MRI (Magnetic Resonance Imaging), and CT (Computed Tomography) scans. A biomarker is a measureable indicator of the severity or presence of some disease state. Previous studies suggest that the change in several imaging biomarkers can predict who will respond to radiation treatment. In this study, patients will undergo CT and MRI scans prior to and after radiation treatment to measure these biomarkers. The purpose of this study is to validate the predictive abilities of biomarkers in terms of determining how patients will respond to radiation treatment. This is a single-center phase II study, which will be conducted at the Princess Margaret Cancer Center. The study will be enrolling up to a total of 90 patients who will be receiving radiation treatment for brain metastases. Patients will be asked to participate within this study for 2 years.
BACKGROUND Obesity is a global epidemic often managed through surgical interventions, such as intragastric balloons. Despite the minimally invasive appeal of intragastric balloons, severe complications, such as gastric outlet obstruction, can occur with their use. The most recent guidelines recommend metabolic and bariatric surgery for specific body mass index categories but rarely discuss the potential complications and required postoperative monitoring. Guidelines encourage metabolic and bariatric surgery for patients with a body mass index of 30-34.9 kg/m² and presence of metabolic disease, or body mass index ≥35 kg/m², regardless of co-morbidities. CASE REPORT We report a case of a 35-year-old woman with severe nausea, vomiting, electrolyte imbalance, and chest pain, leading to ICU admission just 2 weeks after intragastric balloon placement in Mexico. Testing and diagnostics were concerning for metabolic imbalance and heart rhythm changes. Imaging and endoscopic investigations confirmed gastric outlet obstruction, necessitating emergent endoscopic balloon deflation and removal. Following the procedure, her symptoms resolved, and she was discharged with appropriate medication and scheduled follow-up. CONCLUSIONS Given the increasing prevalence of obesity and a corresponding surge in surgical interventions, this case serves as a cautionary tale. Selection of a type of metabolic and bariatric surgery should be patient specific, with the patient involved in the decision making. Rigorous preoperative assessments and sustained postoperative monitoring are imperative. This study aims to guide future research toward enhanced patient selection and prevention of severe complications, thus influencing practice and policy in obesity management.
Patient receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Cycles repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
The total sample size will be up to 40 subjects that complete the full intended implant durations of either 7 days (n=up to 10) or60 days (n=up to 30). Group 1 patients will be enrolled first and at least 5 patients will complete the 7-day implant duration before Group 2 patients begin enrollment. Group 1 and Group 2 subjects can be screened in parallel. Group 2 enrollment will start immediately after at least 5 subjects in Group 1 have successfully completed the 7-day implantation period. Study subjects will have the PortIO device implanted by a qualified physician (Table 5) and then undergo prescribed, standard of care infusion regimen as determined by their treating physician over either the 7-day or the 60-day period. After the intended implant duration and use during the implant period, the device will then be removed and the subject will be followed for safety at 30 days after explant.
BACKGROUND: Cardiac metabolic dysfunction is a hallmark of heart failure (HF). Estrogen-related receptors ERRα and ERRγ are essential regulators of cardiac metabolism. Therefore, activation of ERR could be a potential therapeutic intervention for HF. However, in vivo studies demonstrating the potential usefulness of ERR agonist for HF treatment are lacking, because compounds with pharmacokinetics appropriate for in vivo use have not been available.
METHODS: Using a structure-based design approach, we designed and synthesized 2 structurally distinct pan-ERR agonists, SLU-PP-332 and SLU-PP-915. We investigated the effect of ERR agonist on cardiac function in a pressure overload-induced HF model in vivo. We conducted comprehensive functional, multi-omics (RNA sequencing and metabolomics studies), and genetic dependency studies both in vivo and in vitro to dissect the molecular mechanism, ERR isoform dependency, and target specificity.
RESULTS: Both SLU-PP-332 and SLU-PP-915 significantly improved ejection fraction, ameliorated fibrosis, and increased survival associated with pressure overload-induced HF without affecting cardiac hypertrophy. A broad spectrum of metabolic genes was transcriptionally activated by ERR agonists, particularly genes involved in fatty acid metabolism and mitochondrial function. Metabolomics analysis showed substantial normalization of metabolic profiles in fatty acid/lipid and tricarboxylic acid/oxidative phosphorylation metabolites in the mouse heart with 6-week pressure overload. ERR agonists increase mitochondria oxidative capacity and fatty acid use in vitro and in vivo. Using both in vitro and in vivo genetic dependency experiments, we show that ERRγ is the main mediator of ERR agonism-induced transcriptional regulation and cardioprotection and definitively demonstrated target specificity. ERR agonism also led to downregulation of cell cycle and development pathways, which was partially mediated by E2F1 in cardiomyocytes.
CONCLUSIONS: ERR agonists maintain oxidative metabolism, which confers cardiac protection against pressure overload-induced HF in vivo. Our results provide direct pharmacologic evidence supporting the further development of ERR agonists as novel HF therapeutics.
PURPOSE: To investigate the visual function correlates of self-reported vision-related night driving difficulties among drivers.
METHODS: One hundred and seven drivers (age: 46.06 ± 8.24, visual acuity [VA] of 0.2logMAR or better) were included in the study. A standard vision and night driving questionnaire (VND-Q) was administered. VA and contrast sensitivity were measured under photopic and mesopic conditions. Mesopic VA was remeasured after introducing a peripheral glare source into the participants' field of view to enable computation of disability glare index. Regression analyses were used to assess the associations between VND-Q scores, and visual function measures.
RESULTS: The mean VND-Q score was -3.96±1.95 logit (interval scale score: 2.46±1.28). Simple linear regression models for photopic contrast sensitivity, mesopic VA, mesopic contrast sensitivity, and disability index significantly predicted VND-Q score (P<0.05), with mesopic VA and disability glare index accounting for the greatest variation (21 %) in VND-Q scores followed by photopic contrast sensitivity (19 %), and mesopic contrast sensitivity (15 %). A multiple regression model to determine the association between the predictors (photopic contrast sensitivity, mesopic VA, mesopic contrast sensitivity, and disability index) and VND-Q score yielded significant results, F (4, 102) = 8.58, P < 0.001, adj. R2 = 0.2224. Seeing dark-colored cars was the most challenging vision task.
CONCLUSION: Changes in mesopic visual acuity, photopic and mesopic contrast sensitivity, as well as disability glare index are associated with and explain night driving-related visual difficulties. It is recommended to incorporate measurement of these visual functions into assessments related to driving performance.
Enteral feeding has a vital role in the care of critically ill patients. It is considered a routine patients care in intensive care units. Enteral feeding is also a medical treatment as well as a part of nursing care. It is the preferred route of nutritional support in patients who are incapable of volitional intake. Additionally, it helps to stimulate peristaltic movements of the digestive system, improves blood supply, strengthens the immune system, improves recovery, and reduces physiological stress.

There are many complications associated with enteral feeding that can lead to an interruption of the feeding process, including gastrointestinal disorders, mechanical problems, fluid-electrolyte imbalance, and metabolic complications. Feeding intolerance is the most main digestive complication including nausea, vomiting, diarrhea, excess gastric residual volume, abdominal distention, and constipation.

Aspiration is also a significant side effect of delayed gastric emptying and increased GRV among CIPs. The Society of Critical Care Medicine and the American Society for Parenteral and Enteral Nutrition has recognized aspiration as one of the mutual complications of enteral feeding that should be evaluated before and during the feeding process. Consequently, prolonged ICU stays, and increased duration of mechanical ventilation, and mortality rate are side effects of feeding intolerance and aspiration. Additionally, abdominal massage is one of the complementary and alternative medicine which is significantly grown in recent years. Furthermore, it is an inexpensive, non-invasive intervention, and free from harmful side effects. Besides, it can increase the number of intestinal movements and lead to easier food movement along the gastrointestinal tract. In addition, it allows contraction of the diaphragm more fully, increases the capacity of the lung, and strengthens breathing.
Compositions for oral administration containing metformine or one of its salts as active ingredient, a polyglycolized glyceride having a hydrophilic-lipophilic balance (HLB) above 8 as absorption promoter, and one or more pharmaceutical excipients. The active component is preferably metformine hydrochloride, and the polyglycolized glyceride has an HLB of 12 - 16.  This is preferably used in association with any of the following: polysorbates, alkyl polyoxyethylene ethers, polyoxyethylene fatty acid esters, fatty acids, fatty alcohols, biliary acids and their salts, 1-6C alkanol fatty acid esters, polyol fatty acid esters, polyols with 2 - 6 hydroxy groups, and their mixtures.  The use of fatty acid sorbitan esters is particularly preferred.  The use of a mixture of one or more polyglycol glycerides and esters of sorbitan and a(n) (un)saturated 8-22C (especially 10-14C) fatty acid is especially preferred.  The weight ratio of active material to absorption promoter is preferably 0.001 - 10, especially 0.1- 2.  Also present may be a release-control agent chosen from glycerol palmitostearate, glycerol behenate and/ or hydrogenated ricin oil.
FIELD: medicine, biotechnology, biochemistry. SUBSTANCE: invention relates to DNA-sequences encoding human proteins Tx and Ty related to enzyme converting interleukin-1-beta. Invention involves DNA-sequences encoding human polypeptides relates to enzyme converting interleukin-1-beta that shows protease activity and is able to induce apoptosis. The advantage of invention involves the development of novel polypeptide that can be used for treatment of pathological states mediated by IL-1β or that's are associated with apoptosis. EFFECT: valuable medicinal properties of polypeptide. 21 cl, 9 dwg
Start therapy with Vivelle-Dot 0.0375 mg per day applied to the skin twice weekly. Make dosage adjustments based on the clinical response. Initiate Vivelle-Dot at once in a woman not currently taking oral estrogens or in a woman switching from another estradiol transdermal therapy. In women who are currently taking oral estrogens, initiate treatment with Vivelle-Dot 1 week after withdrawal of oral hormone therapy, or sooner if menopausal symptoms reappear in less than 1 week. Attempts to taper or discontinue Vivelle-Dot at 3 to 6-month intervals.

Give Vivelle-Dot continuously in a woman who does not have an intact uterus. In a woman with an intact uterus, give Vivelle-Dot on a cyclic schedule (for example, 3 weeks on Vivelle-Dot followed by 1 week off Vivelle-Dot).
PROBLEM TO BE SOLVED: To produce quercitol having hypoglycemic actions and useful as a hypotensive agent, a health medicine, etc., without any adverse effects by making a microorganism belonging to the genus Agrobacterium or Salmonella act on myo-inositol. SOLUTION: Myo-inositol is added to a liquid culture medium at pH 7 containing a yeast extract, ammonium sulfate, potassium monohydrogenphosphate, potassium dihydrogenphosphate, magnesium sulfate, etc., and a microorganism belonging to the genus Agrobacterium or Salmonella [e.g. Salmonella typhimurium (IFO13245 strain)] is then inoculated thereinto. Shaking culture is carried out at 27 deg.C for 3 days to make the microorganism act on the myo-inositol and convert the myo-inositol into quercitol. Thereby, the quercitol of high optical purity is efficiently produced at a low cost. The quercitol is useful as a safe hypotensive agent having high effects without any adverse effects and a health medicine, etc., containing the quercitol.
Induction treatment with tiragolumab plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab plus atezolizumab for 21-day cycles.
The present invention relates to a system and method for providing a medical image. The system for providing a medical image according to an embodiment of the present invention includes: one or more viewer modules; a user-specific worklist management module; and a display controller module. The one or more viewer modules display medical images. The user-specific worklist management module provides a user-specific worklist corresponding to a logged-in user, on the basis of the role of the logged-in user, through a worklist interface which provides different functions. The display controller module controls detailed information and medical images for a list, selected from among user-specific worklists, to be displayed through the one or more viewer modules in correspondence with state information on the one or more viewer modules. According to this configuration, since a worklist formed of functions necessary to each user can be provided, all the users can conveniently use same.
Fibroblast growth factor 19 (FGF19) is a hormone synthesized in enterocytes in response to bile acids. This review explores the pivotal role of FGF19 in metabolism, addressing the urgent global health concern of obesity and its associated pathologies, notably type 2 diabetes. The intriguing inverse correlation between FGF19 and body mass or visceral adiposity, as well as its rapid increase following bariatric surgery, emphasizes its potential as a therapeutic target. This article meticulously examines the impact of FGF19 on metabolism by gathering evidence primarily derived from studies conducted in animal models or cell lines, using both FGF19 treatment and genetic modifications. Overall, these studies demonstrate that FGF19 has antidiabetic and antiobesogenic effects. A thorough examination across metabolic tissues, including the liver, adipose tissue, skeletal muscle, and the central nervous system, is conducted, unraveling the intricate interplay of FGF19 across diverse organs. Moreover, we provide a comprehensive overview of clinical trials involving an FGF19 analog called aldafermin, emphasizing promising results in diseases such as nonalcoholic steatohepatitis and diabetes. Therefore, we aim to foster a deeper understanding of FGF19 role and encourage further exploration of its clinical applications, thereby advancing the field and offering innovative approaches to address the escalating global health challenge of obesity and related metabolic conditions.
NEW MATERIAL:A compound, expressed by the formula (k and n are 1 or 2; land n are 0,1,2 or 3), which may be substituted at an optional position by a trifluoromethyl group. EXAMPLE:Perfluoro-2-azatricyclo[6.3.0.0<2>,<6>]undecane. USE:Useful as a blood substitute, oxygen transporting component in the oxygen transportation fluid therapy, etc., capable of dissolving a large amount of oxygen, metabolically inert, and excretive rapidly to the outside of the body. PROCESS:A perhydro compound which is a raw material compound is dissolved in anhydrous hydrogen fluoride in an electrolytic cell. The resultant solution is then electrolyzed at 4-8V, 0.1-10A/dm<2> anodic current density and 4-12 deg.C electrolytic temperature. A mixture solution of an aqueous solution of an alkali with an amine type compound are added thereto, and the fluorine compound is decomposed under refluxing and purified to give the aimed compound expressed by the formula.
School counselors deliver the HSI intervention which focuses on improving focus and efficiency of work completion. This consists of 16, 20-minute sessions, with the student and two joint family meetings.
A heparinised saline solution of 25,000 IU of heparin per 1 litre of intravenous normal saline (0.9% NaCl) solution is used with a dosage of 20 ml of solution per 100 ml of collected blood. This type of solution is not commercially available and is made locally. This solution is used in the cell salvage process to prevent coagulation.
PURPOSE: To obtain an effective adjuvant composition capable of being used for preparation of animal or human vaccine. CONSTITUTION: This adjuvant composition is obtained by formulating (A) at least one kind of synthetic hydrophobic lipopolysaccharide capable or incapable of supplying an anion group, preferably sulfate group, preferably having 0.2-4 average ratio to saccharide group, <=9, especially <=4 hydrophilic-hydrophobic balance (HLB) with (B) a interface-forming component, preferably a liquid which is immiscible with an aqueous phase (e.g. oil originating from animals or plants, preferably squalane) or a solid which is insoluble in the aqueous phase [e.g. Al(OH)3 or AlPO4 ] as essential components and as necessary, further, adding (C) an aqueous solute, e.g. a salt solution, a phosphoric acid buffer solution or pure water thereto. The composition can be used as vaccine by mixing with immunogen.